Research programme: ImmunoVEX vaccines - Sanofi-Aventis

Drug Profile

Research programme: ImmunoVEX vaccines - Sanofi-Aventis

Alternative Names: ImmunoVEX vaccines research programme - Sanofi-Aventis

Latest Information Update: 18 Mar 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator sanofi-aventis
  • Class Vaccines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Unspecified

Most Recent Events

  • 31 May 2006 Discontinued - Preclinical for Undefined indication in France (unspecified route)
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
  • 22 Jun 2001 Preclinical development for Undefined in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top